Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir once-monthly versus daily emtricitabine + tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis in cisgender women
2021-001289-39Phase 3
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Incidence Rate Per Year of Confirmed HIV-1 Infections.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-001289-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001289-39.